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Abstract
Background: Access to antiretroviral therapy has dramatically expanded in Africa in recent years, but there are no
validated approaches to measure treatment adherence in these settings.
Methods: In 16 health facilities, we observed a retrospective cohort of patients initiating antiretroviral therapy. We
constructed eight indicators of adherence and visit attendance during the first 18 months of treatment from data
in clinic and pharmacy records and attendance logs. We measured the correlation among these measures and
assessed how well each predicted changes in weight and CD4 count.
Results: We followed 488 patients; 63.5% had 100% coverage of medicines during follow-up; 2.7% experienced a
30-day gap in treatment; 72.6% self-reported perfect adherence in all clinic visits; and 19.9% missed multiple clinic
visits. After six months of treatment, mean weight gain was 3.9 kg and mean increase in CD4 count was 138.1
cells/mm3.
Dispensing-based adherence, self-reported adherence, and consistent visit attendance were highly correlated. The
first two types of adherence measure predicted gains in weight and CD4 count; consistent visit attendance was
associated only with weight gain.
Conclusions: This study demonstrates that routine data in African health facilities can be used to monitor
antiretroviral adherence at the patient and system level.
Background
Global health initiatives have introduced antiretroviral
therapy (ART) to ever-increasing numbers of HIV
patients. Successful therapy depends on life-long adher-
ence to these medications. Thus far, large-scale African
ART program have reported mixed results on patient
adherence to antiretrovirals (ARVs),[1] with some pro-
grams reporting high levels,[2,3] and some reporting
much lower levels[4]. With rapidly expanding access to
ARVs in resource-poor settings, it will be vital to moni-
tor adherence and to identify interventions that can
encourage sustained adherence.
Accurate assessment of adherence is critical to maxi-
mize clinical efficacy and minimize the potential
population risks associated with drug resistance. How-
ever, no validated approaches exist to measure adher-
ence, especially in low resource settings with potentially
poor data availability.
Patient self-report about recent adherence is a com-
mon assessment method due to its relative ease and low
cost of data collection, but self-reports tend to overesti-
mate adherence[5,6]. In addition, self-report adherence
measures have been operationalized in different ways[7].
A recent meta-analysis showed that self-report adher-
ence measures are predictive of clinical outcomes,[8] a
finding that has been replicated in resource poor set-
tings [2-4,9]. However, no studies have validated
whether routine self-report data in medical or pharmacy
records are predictive of clinical outcomes.
Pill counts, like self-reports, can overestimate adher-
ence when compared with electronic medication
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separate recording process in the pharmacy that is often
not part of routine dispensing operations. Nevertheless,
pill counts have also been shown to be associated with
viral load and CD4 counts[6].
Pharmacy refill records are commonly used in settings
with electronic pharmacy data systems to calculate
adherence indicators,[10,11] either percentage of days
within a defined period covered by medicines dispensed
or occurrence of gaps between dispensings. Several stu-
dies have shown associations between dispensing-based
adherence measures and clinical outcomes, including
viral load and CD4 counts[12,13]. Pharmacy refill
approaches have not been extensively tested in settings
with manual dispensing records, where data complete-
ness and quality may be problematic.
Consistency of clinic attendance is potentially another
way to assess continuity of care and risk for poor adher-
ence. Because failure to attend clinic when expected is
objective and easy to ascertain in most record systems,
inconsistency of attendance may identify patients in
need of outreach or adherence counseling.
In 2006 the International Network for Rational Use of
Drugs (INRUD) and national HIV/AIDS programs in
five East African countries began the five-year Initiative
on Antiretroviral Adherence (IAA) to develop practical
interventions to improve adherence to ART in routine
treatment settings. They found wide variations in defini-
tions and practice in measuring and reporting adher-
ence[14]. To address this gap, the INRUD-IAA group
has developed and pilot tested methods and indicators
to assess adherence at health facilities using patient
interviews and the types of routine data available in
these settings, which are reported in a companion publi-
cation[15]. These indicators can be used to measure the
success of health facilities in maintaining patients on
treatment and to evaluate the impact of interventions.
This study was designed to assess the correlation
between several of the INRUD-IAA measures: patient
self-reports and pill counts (documented in clinical and
pharmacy records); pharmacy dispensing-based indica-
tors; and attendance consistency. To validate these mea-
sures, we also assessed the extent to which they predict
changes in weight and CD4 count 5-14 months after
start of ART in treatment naïve patients.
Methods
Overall study design
We conducted a retrospective cohort study in 16 HIV/
AIDS treatment facilities in Ethiopia, Kenya, Rwanda,
and Uganda using data from medical and pharmacy
records on attendance, medication dispensing, pill
counts or self-report adherence, demographic and clini-
cal covariates, and clinical outcomes.
Facility sample
From 80 facilities included in our pilot studies to test
adherence indicators, [as referenced above] we selected
four per country to represent the range of infrastruc-
tures and patient populations. Facilities that primarily
conduct AIDS clinical research were excluded and no
more than one referral center was included in each
country.
Patient sample
The study sample targeted 30 treatment naïve patients
per facility who initiated ART 8-24 months prior to data
collection and who met the following inclusion criteria:
(a) ≥ 18 years old; (b) no previous exposure to ART
except for prevention of mother to child transmission
(PMTCT); (c) follow-up data for ≥ 6m o n t h sa f t e rA R T
initiation, as indicated by one or more recorded clinic
visits in two consecutive 3-month periods after initia-
tion; (d) at least one adherence self-report or pill count
in medical or pharmacy records in these two quarters;
(e) data available on prescribed ART regimen and quan-
tity dispensed during the follow-up period; (f) at least
one CD4 count recorded within 3 months prior to
initiation and in the 18 months after initiation.
Data collection and variables
Trained data collectors abstracted data from patient
intake records, appointment schedules, and medical and
pharmacy records for 18 months following ART initia-
tion or until the date of data collection, whichever
occurred first.
All data for measuring patient adherence were
extracted from routine clinic records, where they had
been recorded by the treating clinician, nurse, or phar-
macist during the clinic visit. Data for calculating adher-
ence measures included: self-reported adherence; pill
counts, documented as number of days of therapy
remaining from previous dispensings; and type and days
of antiretroviral medicines dispensed. Self-reported
adherence was typically documented in medical records
as perfect (which we coded as 1), good (2), or poor (3).
In Ethiopia, self-reports were documented as good/fair
vs. poor; because of the difference in coding, cases from
Ethiopia were excluded from statistical analyses of self-
reports. We calculated consistency of clinic attendance
using scheduled and actual visit dates. Pill counts were
recorded for <38% of clinic visits and the information
recorded varied, so we dropped pill count adherence
from the analysis.
We constructed the following adherence measures at
every follow-up visit after ART initiation: (a) average
self-reported adherence from initiation to visit date; (b)
whether the patient ever self-reported poor adherence;
(c) percentage of days since ART initiation covered by
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experienced a gap of >30 days without ARVs, assuming
daily consumption until available supply was exhausted;
(e) percentage of visits to date that occurred on or
before the scheduled date and the percentage within 3
days after the scheduled date; and (f) percentage of visits
that occurred on or before the expected date of finishing
the ARVs dispensed in the previous visit (usually 30
days supply). The last indicator was developed as an
alternative to the attendance-based indicators to accom-
modate systems where data on the dates of scheduled
visits are not readily available.
Health facility information collected included type
(national, provincial, district, or other hospital, or health
center), location (capital, other urban, or rural area), and
management (public, private, mission, other non-gov-
ernmental organization). Patient demographic informa-
tion included age, gender, marital status, living situation,
education, occupation, and presence of a treatment sup-
port partner. Clinical information included WHO stage
of HIV/AIDS on ART initiation, evidence of ARVs to
prevent mother to child transmission, evidence of tuber-
culosis at ART initiation, duration of ART, and ART
regimen prescribed at each visit. We also extracted
symptoms or diagnoses that might indicate possible side
effects, opportunistic infections, or significant clinical
events associated with HIV.
Our primary outcomes were weight and CD4 counts.
We recorded weight in kilograms at baseline and at
every subsequent visit, and calculated weight gain (or
loss) since the initiation of therapy at each visit. Treat-
ment protocols typically call for patients to have a fol-
low-up CD4 test within the first 6 months after
initiating ART, although because of limitations in
laboratory availability, this may stretch to a longer inter-
val. We captured the dates and results of all CD4 tests
from 3 months prior to initiating ART until the end of
follow-up. For patients with at least one CD4 count
recorded between 4 and 9 months after initiation of
ART, we calculated changes between the baseline and
the date of the follow-up CD4 count.
Data management and analysis
Country data collectors entered data twice into standar-
dized Excel spreadsheets; data entry differences and data
errors were resolved by study staff. Using Pearson pro-
duct moment coefficients (for continuous measures) and
Kendall tau rank correlation coefficients (when one or
both measures were binary), we estimated correlations
among the different adherence and visit measures.
We used generalized estimating equations (GEE) to
predict weight change from baseline to each clinic visit
during the first 270 days after ART initiation and ordin-
ary least squares regression models to predict change in
CD4 count from baseline to the follow-up CD4 test.
Each adherence indicator wasm o d e l e ds e p a r a t e l yf o r
each clinical outcome; because of the difference in the
way the indicator was reported, patients from Ethiopia
were excluded from analyses modeling average self-
reported adherence. All models included: gender, age
(30 or younger, 31-40, >40 years), whether married,
capital-urban-rural clinic location, baseline CD4 level,
WHO stage at ART initiation (stage 1 or 2 vs. stage 3
or 4), time since ART initiation, evidence of TB at ART
initiation, evidence of side effects or opportunistic infec-
tions since treatment initiation, number of different
ART regimens, and whether the patient was ever treated
w i t hap r o t e a s ei n h i b i t o r ;w e i g h tc h a n g em o d e l sa l s o
included baseline weight. All analyses were performed in
SAS version 9.1 (SAS Institute, Cary, NC).
Ethical approval
This study was approved by the AIDS Control Programs
of the participating countries and by the Harvard Pil-
grim Health Care Human Studies Committee.
Results
Demographic and clinical characteristics
The overall sample consisted of 488 patients. Of patients
screened for sample inclusion, 7.4% were under age 18,
3.9% had evidence of previous ART; 4.8% did not have
clinic visits in each of the first two quarters after initiat-
ing ART, and 8.6% did not have adherence self-reports
in the first two post-initiation quarters. Gender, age, and
WHO stage at ART initiation were similar between
included and excluded patients.
Table 1 describes key demographic and clinical char-
acteristics of the overall study group and the subgroup
having a CD4 test within the target window of 91 to
270 days after treatment initiation. About 63% of
patients were women and average age was 36 years
(SD = 8.3). Half had a primary school education and
another third had attended secondary school or college;
about 40% were currently unemployed. The sample was
predominantly treated in urban health facilities (76%),
nearly two-thirds in government facilities. About half of
patients were WHO stage 3 when initiating ART and
another 25% initiated treatment at stage 2. In the base-
line CD4 test, 37% of patients had CD4 counts of ≤ 100,
40% had counts of 101-200, and 23% were ≥ 201. Males
had an average baseline weight of 57.2 kg (SD = 9.7),
while women averaged 52.9 kg (SD = 9.2).
Table 2 presents the values of the main study adher-
ence, attendance, and clinical outcome measures at the
time of follow-up measurement. Patients generally main-
tained high rates of adherence to therapy in the first six
to nine months of treatment. Over 83% had ART cover-
age rates greater than 95% and another 14% had
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had coverage rates less than 80% or experienced a gap
in therapy of ≥ 30 days during the follow-up period.
Patient self-reports mirror the positive results of the
dispensing adherence measures. The average self-
reported adherence score was 1.17 (out of 3). Nearly
three-quarters of patients (72.6%) reported perfect
adherence in all clinic visits; only 3% of patients
reported poor adherence in any visit.
Patients averaged more than one visit per month dur-
ing follow-up and most attended a high percentage of
visits as scheduled. About 20% of patients did not come
on the day expected and only 6% failed to appear within
3 days for more than one in five of their visits. For the
measure based on attending before all medicines dis-
pensed in the previous visit were finished, consistency
appears worse; 45% of patients did not come on or
before the day on which medicines were finished for
more than one in five of their visits. Since this measure
does not account for medicines remaining from earlier
visits, it may overestimate the frequency of running out
of medicines.
Finally, ART initiation is clearly associated with
improvements in clinical outcomes. Patients gained an
average of 3.9 kg (SD = 5.1) in the first six months of
treatment. In the subgroup with a follow-up CD4 test,
the average improvement in CD4 count was 138 (SD =
125) cells/mm
3 during that period.
Correlations among adherence measures
Table 3 reports correlations among the adherence mea-
sures. The patterns and overall strength of the correla-
tions between the different measures suggest that they
address related behavioral domains.
The dispensing-based coverage measures were all
highly inter-correlated, which is not surprising since
they are derived from the same data source. The dispen-
sing-based measures are also highly correlated with the
attendance-based measures, suggesting that patients
who present regularly for appointments maintain a
more continuous supply of medicines. Self-report mea-
sures (average self-report in prior visits or ever reporting
less than perfect adherence) are both significantly corre-
lated with percent of days covered and coverage >95%,
as well as with regularly attending clinic on the sched-
uled day or within 3 days.
Adherence predicting weight change
Table 4 presents estimates from multivariate GEE mod-
els examining the relationship between the various
adherence measures and weight gain. Controlling for
demographic and clinical factors, the average adjusted
monthly weight gain during the first 9 months of treat-
ment was dramatic (Figure 1). The categorical dispen-
sing-based coverage measure was significantly associated
with greater weight gain during follow-up (p = 0.04 for
inclusion of this variable in the model). Higher rates of
medication coverage were associated with greater weight
gain (Figure 2). Patients with <80% coverage gained sig-
nificantly less weight than those who were more adher-
ent, but weight gain did not differ significantly by
Table 1 Demographic and clinical characteristics of
patients in the overall study cohort and in the subgroup
with follow-up CD4 tests 4 to 9 months after ART
initiation.
Total
(n = 488)
With CD4 test
(n = 409)
Female 62.5% 63.1%
Age
30 & under 29.3% 29.6%
31-40 43.4 42.8
41 & over 27.3 27.6
Education
None 15.5% 16.8%
Primary 46.7 47.3
Secondary or greater 37.8 36.0
Married currently 44.1% 44.9%
Living
Alone 6.0% 6.1%
With child only 24.5 23.8
With adult +/- child 69.6 70.1
Occupation
Employed 28.3% 28.5%
Self-employed 32.2 32.0
Unemployed 39.4 39.5
Treated in government facility 63.5% 61.4%
Treatment location
Clinic in capital 49.8% 50.4%
In other urban area 26.4 25.4
In rural area 23.8 24.2
WHO stage at initiation
Stage 1 8.9% 7.9%
Stage 2 25.4 26.5
Stage 3 54.4 53.3
Stage 4 11.3 12.3
Has treatment support partner 88.7% 89.7%
Evidence of previous PMTCT (female only) 6.2% 4.7%
Evidence of current or prior TB at initiation 15.2% 13.2%
Baseline CD4 value
< = 100 37.4% 36.7%
101-200 40.4 42.5
201-350 20.9 19.3
351 an above 1.6 1.4
Weight in kg (SD) at initiation
Males 57.2 (9.2) 57.1 (9.2)
Females 52.9 (9.7) 52.9 (9.8)
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mates from the model, typical male patients in this
cohort gained 5.9 kg by month 9 if perfectly adherent
and 3.6 kg if <80% adherent, while female patients
gained 6.2 kg and 3.9 kg respectively.
A total of 13 patients experienced a gap in therapy of
>30 days during follow-up. Average medication coverage
for these patients was 53% compared to 98% for the
remaining cohort members. Based on the controlled
GEE models, patients experiencing a 30-day gap in
treatment gained an estimated 3.3 kg less (-5.2, -1.3)
than those who did not experience such a gap, averaged
across all visits during the follow-up period.
A self-report of less than perfect adherence during any
clinic visit since initiation of therapy was significantly
associated with gaining 1.1 kg less (-2.0, -0.3) than those
who always self-reported perfect adherence. Average
self-reported adherence during all prior visits was also
significantly related to weight gain. Compared to
patients reporting perfect adherence in all visits, patients
who averaged between good and perfect self-reported
adherence gained 1.1 kg less (-2.1, -0.1), and patients
w h oa v e r a g e dg o o da d h e r e n c eo rw o r s eg a i n e d1 . 2k g
less (-2.4,-0.1).
All measures of consistent clinical attendance were
s i g n i f i c a n t l ya s s o c i a t e dw i t hw e i g h tg a i n .B a s e do nG E E
Table 2 Adherence and clinical outcome measures at visit nearest to 180 days after initiation or at second CD4 test in
subgroup with test in months 4 to 9.
Total
(n = 488)
With CD4 test
(n = 409)
Average number of days since treatment initiation (min, max) 178
(124,337)
188
(98,270)
Dispensing-based adherence
% of days covered since ART start
< 80% 2.9% 2.4%
80% to <85% 2.7 2.0
85% to <90% 2.9 3.9
90% to <95% 8.0 8.1
95% to <100% 20.1 19.6
100% 63.5 64.1
% with gap in treatment >30 days 2.7% 3.4%
Self-report adherence
Average (s.d.) number of self-reports recorded in medical record during follow-up 5.7 (1.8) 5.4 (2.0)
Average (s.d.) of all self-reports * 1.17 (0.39) 1.16 (0.33)
% all self-reports perfect * 72.6% 74.4%
% any self-report poor * 3.0% 2.9%
Appointment keeping
Average number (s.d.) of visits 6.4 (1.1) 6.0 (1.6)
% visits on/before scheduled day
< 80% 19.9% 18.1%
80% to <90% 22.1 20.5
90% to 100% 58.1 61.4
% visits ≤ 3 days after scheduled
< 80% 5.9% 5.7%
80% to <90% 13.1 11.1
90% to 100% 81.0 83.2
Dispensing-based appointment keeping
% of visits before finishing ARVs dispensed during previous visit
< 80% 44.9% 44.0%
80% to <90% 27.5% 27.1
90% to 100% 27.7% 28.9
Change in clinical outcome measures
Average (s.d.) increase in CD4 count NA 138.1 (125.5)
Average (s.d.) weight gain (kg) 3.9 (5.1) 3.8 (4.8)
* Self-reports were recorded in medical records as perfect (coded as 1), good (2), or poor (3); cases from Ethiopia (n = 120 total, n = 96 with CD4 test) were
excluded from analysis because self-reports there were recorded as good/fair vs. poor.
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within 3 days of the scheduled day experienced a 1.4 kg
lower (0.3, 2.5) weight gain than those who attended a
greater percentage of their visits on time.
Adherence predicting change in CD4 count
Table 5 presents results from the linear regression mod-
els examining the adherence measures as predictors of
changes in CD4 count. As with weight gain, the dispen-
sing-based adherence measures were significantly asso-
ciated with changes in CD4 count during follow-up
(Figure 3). Patients with 100% coverage of dispensed
medicines experienced an average gain in CD4 count of
148.8 cells/mm3 (133.7, 164.0) between tests, compared
to patients with <80% medicines coverage who gained
an average 51.5 cells/mm3 (-25.6, 128.6). Patients with
adherence from 80% to 100% experienced intermediate
gains. Similarly, patients with a coverage gap longer
than 30 days had gains in CD4 count that were an esti-
mated 80.7 cells/mm3 less (-149.3, -12.1) than those
without a gap.
Average self-reported adherence recorded in medical
records up to the date of the second CD4 test had an
overall significant relationship with CD4 gain. Compared
to patients who always reported perfect adherence, gains
in CD4 counts among patients who averaged between
good and perfect self-reported adherence were a non-
significant 27.0 cells/mm3 less (-66.1, 12.1), while CD4
gains among patients who averaged good self-reported
adherence or worse were 67.2 cells/mm3 less (-120.8,
-13.7), a difference which was significant. Patients with
any report of less than perfect adherence experienced
gains in CD4 count that were 40.2 cells/mm3 lower
(-73.6, -6.8) than those who always reported perfect
adherence.
The visit-based attendance measures were not signifi-
cantly associated with improvements in CD4 counts.
Discussion
This validation study shows that adherence and atten-
dance indicators measured using routine data that exist
in typical African HIV/AIDS care settings were signifi-
cantly associated with key clinical outcomes during the
early treatment period. Consistency of clinic visits and
dispensing-based adherence indicators were both mod-
erately to highly associated with weight gain during the
first nine months after ART initiation. In addition, both
dispensing-based adherence measures and self-reported
Table 3 Correlations among dispensing, self-report, and attendance-based adherence measures at time of clinic visit
closest to 180 days after treatment initiation.
Correlation
Significance
N
(bold = p <
0.05)
Coverage
>80%
Coverage
>95%
Coverage
gap >30
days
Average
self-report
adherence *
Any self-report
adhe-rence less
than perfect*
% of visits on
or before
scheduled
day**
% of visits
within 3 days of
scheduled day**
% of visits
before last
dispensing
finished
% of days
covered
0.335
< .0001
488
0.744
< .0001
488
-0.321
< .0001
488
-0.186
.0004
358
-0.185
.0004
368
0.324
< .0001
458
0.357
< .0001
458
0.560
< .0001
488
Coverage >80%
&
0.388
< .0001
488
-0.734
< .0001
488
-0.002
.9762
358
0.010
.8474
368
0.186
< .0001
458
0.305
< .0001
458
0.237
< .0001
488
Coverage >95%
&
-0.374
< .0001
488
-0.178
.0007
358
-0.162
.0018
368
0.264
< .0001
458
0.376
< .0001
458
0.399
< .0001
488
Coverage gap
>30 days &
-0.003
.9480
358
-0.010
0.8471
368
-0.120
.0104
458
-0.222
< .0001
458
-0.206
< .0001
488
Average self-
report adherence
0.983
< .0001
358
-0.136
.0104
357
-0.160
.0024
357
0.072
0.1725
358
Any self-report
adherence less
than perfect &
-0.141
.0069
367
-0.164
.0016
367
-0.044
0.3961
368
% visits on/
before scheduled
day
0.630
< .0001
458
0.360
< .0001
458
% visits within 3
days of
scheduled day
0.367
< .0001
458
* Self-reports (n = 368) coded 1 = perfect, 2 = good, 3 = poor; excludes n = 120 cases from Ethiopia where self-reports were scored good/fair vs. poor
** n = 458 for appointment keeping variables due to missing scheduled visit dates
& Kendall tau rather than Spearman rank-order correlations are reported when these variables are correlated with each other
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counts in that period. Given that the data were
extracted from routine records and are likely to contain
random errors, the strengths of these relationships are
likely to be underestimated.
In our study, the questions used to determine the
adherence levels that were recorded in medical records
were unknown and likely inconsistent across providers
and treatment centers; in addition, self-reported adher-
ence was recorded differently in Ethiopia than in the
other three countries, requiring us to drop these cases
from statistical analysis. Nevertheless, self-reported
adherence measures showed promise. When measured
in research settings, self-reported adherence has been
reliably predictive of positive clinical outcomes[2-4,9].
Attention should be paid to strengthening the
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Figure 1 Adjusted monthly weight gain in the first 9 months following initiation of ART. Adjusted monthly weight gain in the first 9
months following initiation of ART in all patients in the sample estimated from generalized estimating equations. Model adjusts for gender, age
category (30 or younger, 31-40, >40 years), whether married, capital-urban-rural location, baseline CD4 level, baseline weight, WHO stage at ART
initiation (stage 1 or 2 vs. stage 3 or 4), evidence of TB at ART initiation, any evidence in medical record of side effect or opportunistic infection
since treatment initiation, number of different ART regimens since initiation, and whether the patient was ever treated with a protease inhibitor.
Table 4 Estimates from GEE models of indicators of adherence and appointment keeping as predictors of weight gain
(in kilograms) in the first 9 months after ART initiation.
Parameter Estimate P-value Confidence Interval
Coverage (vs. 100% coverage) *
<80% of days covered -2.24 0.0012 -3.59, -0.89
80% to <90% of days covered -0.51 0.3517 -1.59, 0.57
90% to <100% of days covered -0.52 0.1504 -1.23, 0.19
Gap >30 days (vs. no gap in coverage) -3.26 0.0010 -5.20, -1.31
Average self-report (vs. all self-reports perfect) ** &
Better than good but less than perfect -1.06 0.0368 -2.05, -0.06
Good or worse -1.23 0.0352 -2.38, -0.09
Any self-report less than perfect (vs. all perfect) & -1.14 0.0062 -1.96, -0.32
<80% of visits on day scheduled -0.72 0.0413 -1.41, -0.03
<80% of visits within 3 days of schedule -1.38 0.0127 -2.47, -0.29
<80% of visits before medicines finished -0.71 0.0140 -1.28, -0.14
Key: All models use variables measured on the day of each follow-up visit and include all visits up to 270 days following ART initiation. For all models except
those involving self-reported adherence, n = 479 cases and n = 3384 follow-up clinic visits; for self-report adherence models, n = 354 cases and n = 2404 follow-
up clinic visits. Models include: gender, age category (30 or younger, 31-40, >40 years), whether married, capital-urban-rural location, baseline CD4 level, baseline
weight, WHO stage at ART initiation (stage 1 or 2 vs. stage 3 or 4), time since ART initiation (in nine 30-day categories up to 270 days), evidence of TB at ART
initiation, any evidence in medical record of side effect or opportunistic infection since treatment initiation, number of different ART regimens since initiation,
ever treated with a protease inhibitor.
* GEE type 3 score statistic for inclusion of 3 coverage terms in model, p = 0.0358
** GEE type 3 score statistic for inclusion of 2 self-report terms in model, p = 0.0331
& Models exclude cases from Ethiopia which assessed self-reported adherence differently
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routine records. Self-reported adherence measures
(particularly indication of less than perfect adherence
(i.e., missing any doses in a recent period, which is rela-
tively easier to assess) would be useful both in clinical
management of individual patients and in monitoring
adherence in patient populations.
Our study has several notable limitations. First, we could
not examine the validity of the INRUD-IAA indicators as
predictors of patient dropout because study inclusion cri-
teria required patients to remain in treatment for 4 to
6 months. This requirement was needed in order to obtain
sufficient data to measure the dispensing-based and atten-
dance-based measures, which depend on data from
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Figure 2 Adjusted weight gain and adherence at nine months after initiation of ART. Adjusted weight gain for a typical patient at the end
of the nine-month period following initiation of ART by percentage of days covered with antiretroviral therapy. GEE model adjusts for gender,
age category (30 or younger, 31-40, >40 years), whether married, capital-urban-rural location, baseline CD4 level, baseline weight, WHO stage at
ART initiation (stage 1 or 2 vs. stage 3 or 4), evidence of TB at ART initiation, any evidence in medical record of side effect or opportunistic
infection since treatment initiation, number of different ART regimens since initiation, ever treated with a protease inhibitor, and time since ART
initiation. Typical patients were age 31-40, living in the capital, married, with baseline CD4 = 139.8, baseline weight = 52.8 kg for women and
57.2 kg for men, an average of 1.6 different ART regimens, no side effects or opportunistic infections during treatment, and never on PI.
Table 5 Estimates from general linear models of indicators of adherence and appointment keeping as predictors of
change in CD4 count at time of follow-up CD4 test between 4 and 9 months after ART initiation.
Parameter estimate P-value Confidence interval
Coverage (vs. 100% coverage) *
<80% of days covered -97.3 0.0156 -176.1, -18.5
80% to <90% of days covered -28.8 0.2817 -81.2, 23.7
90% to <100% of days covered -22.1 0.1224 -50.2, 6.0
Gap >30 days (vs. no gap in coverage) -80.7 0.0212 -149.3, -12.1
Average self-report (vs. all self-reports perfect) ** &
Better than good but less than perfect -27.0 0.1752 -66.1, 12.1
Good or worse -67.2 0.0141 -120.8. -13.7
Any self-report less than perfect (vs. all perfect) & -40.2 0.0186 -73.6, -6.8
<80% of visits on day scheduled -7.3 0.6759 -41.7, 27.1
<80% of visits within 3 days of schedule -25.5 0.3605 -80.3, 29.3
<80% of visits before medicines finished -8.6 0.5091 -34.1, 16.9
Key: All models use variables measured at the time of the follow-up CD4 test. For all models except those involving self-reported adherence, n = 401 cases; in all
models involving self-report, n = 296 cases. Models include: gender, age category (30 or younger, 31-40, >40 years), whether married, capital-urban-rural location,
baseline CD4 level, WHO stage at ART initiation (stage 1 or 2 vs. stage 3 or 4), time since ART initiation (in nine 30-day categories up to 270 days), evidence of TB
at ART initiation, any evidence in medical record of side effect or opportunistic infection since treatment initiation, number of different ART regimens since
initiation, ever treated with a protease inhibitor.
* F-test for inclusion of 3 coverage terms in model, p = 0.0465
** F-test for inclusion of 2 self-report terms in model, p = 0.0316
& Models exclude cases from Ethiopia which assessed self-reported adherence differently
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Page 8 of 10multiple visits. Most adherence failures occur early in the
course of treatment. Our methods preclude examining the
predictors and impacts of these early adherence failures.
We measured the validity of the adherence measures
in predicting clinical changes soon after the start of
therapy. Further analyses would be needed to assess the
predictive validity of these measures for patients in
t r e a t m e n tf o rl o n g e rp e r i o d s .W ea l s ow e r eu n a b l et o
assess body mass index as a measure of nutritional sta-
tus at the initiation of therapy, a potential confounder
for post-initiation weight gain, due to the lack of data
on height in the clinical record. Although food supple-
ments offered at clinics would be another potential con-
founder of the relationship between adherence and early
weight gain, we are not aware of any supplements
offered at study facilities during the study period.
We did not assess the consistency of self-reported
adherence in clinical and pharmacy records and as gath-
ered by trained interviewers using a systematic method.
These validation analyses will be part of future studies
of the INRUD-IAA adherence indicators.
Despite these limitations, our study is the first to
demonstrate that standardized measures of treatment
adherence and attendance derived from routine data in
African ART treatment settings are valid predictors of
clinical outcomes among newly treated patients. Because
these data are already available in most settings, they
should be more widely used for monitoring adherence
to ART and evaluating interventions.
Conclusions
This study demonstrates that adherence measures derived
from dispensing data in pharmacy records, self-report data
in medical records, and attendance logs predict key clinical
outcomes related to individual patient success in treat-
ment. However, a more important use would be as popu-
lation measures to characterize the overall success of
treatment programs or health facilities in maintaining
patients on therapy. With such data, it would be possible
to target quality improvement activities to programs, facil-
ities, and ultimately patients that are in greatest need.
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